Silicon Valley's longevity drug obsession is facing its first real reality check

Silicon Valley's longevity drug obsession is facing its first real reality check

Bryan Johnson, the tech entrepreneur who turned his body into a public experiment, stopped taking Rapamycin in September 2024 after several years of self-testing the drug.

The immunosuppressant, which is clinically used to prevent organ rejection, had been a cornerstone of his longevity regimen since 2019. Over the years, he documented his dosages, blood work, and subjective responses in meticulous detail, sharing the data with his online audience.

The drug at the center of the debate

Rapamycin was originally discovered in soil samples from Easter Island in the 1970s. It works by inhibiting a protein complex called mTOR, which regulates cell growth and metabolism.

In laboratory studies, the drug has extended lifespan in mice, yeast, and worms. These results have fueled intense interest among Silicon Valley biohackers and longevity investors, many of whom obtain the drug through off-label prescriptions or gray-market sources.

Why Johnson stopped

Johnson cited concerns about side effects that emerged over time, including:

• Elevated blood glucose levels
• Mouth ulcers
• A general feeling of metabolic disruption

He stated in a public update that the risks no longer justified the potential benefits for his specific biology, though he emphasized that others might respond differently.

The broader implications

Johnson's decision arrives at a moment when the longevity industry is under increasing scrutiny. Several high-profile startups have faced setbacks in clinical trials, and regulators have begun to question the safety of long-term Rapamycin use in healthy individuals.

Key points of concern include:

1. The drug's immunosuppressant properties, which could increase infection risk over decades of use
2. Lack of large-scale human trials for anti-aging purposes
3. The difficulty of measuring aging itself as a clinical endpoint

Despite these challenges, the field continues to attract significant venture capital. Companies are exploring alternative compounds that target the same biological pathways with fewer side effects.

What comes next

Researchers are now focusing on next-generation mTOR inhibitors and intermittent dosing protocols that might preserve benefits while minimizing harm. Some labs are also investigating whether the drug's effects vary significantly by sex, age, and genetic background.

For now, the longevity community remains divided. Some practitioners continue to prescribe Rapamycin to patients, while others have followed Johnson's lead in stepping back. The coming years of clinical data will determine whether the drug becomes a standard preventive therapy or remains a speculative experiment.